Recent

% | $
Quotes you view appear here for quick access.

Gilead Sciences Inc. Message Board

  • bluecheese4u bluecheese4u Feb 4, 2013 6:09 PM Flag

    Gilead Sciences Announces Fourth Quarter and Full Year 2012 Financial Results

    Gilead Sciences Announces Fourth Quarter and Full Year 2012 Financial Results

    - Fourth Quarter Product Sales of $2.51 billion, Up 18 percent Year over Year -

    - Full Year 2012 Product Sales of $9.40 billion, Up 16 percent over 2011 -

    - Full Year 2012 Operating Cash Flows of $3.19 billion -

    FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 4, 2013-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2012. Total revenues for the fourth quarter of 2012 increased 18 percent to $2.59 billion, from $2.20 billion for the fourth quarter of 2011. Net income for the fourth quarter of 2012 was $762.5 million, or $0.47 per diluted share compared to $665.1 million, or $0.43 per diluted share for the fourth quarter of 2011. Non-GAAP net income for the fourth quarter of 2012, which excludes acquisition-related, restructuring and stock-based compensation expenses, was $823.4 million, or $0.50 per diluted share compared to $743.1 million, or $0.49 per diluted share for the fourth quarter of 2011. All earnings per share and share have been adjusted to reflect the two-for-one stock split that became effective on January 25, 2013.

    Full year 2012 total revenues were $9.70 billion, up 16 percent compared to $8.39 billion for 2011. Net income for 2012 was $2.59 billion, or $1.64 per diluted share, compared to $2.80 billion, or $1.77 per diluted share for 2011. Non-GAAP net income for 2012, which excludes acquisition-related, restructuring and stock-based compensation expenses, was $3.08 billion, or $1.95 per diluted share, compared to $3.04 billion, or $1.93 per diluted share for 2011.

    Product Sales

    Product sales increased 18 percent to $2.51 billion for the fourth quarter of 2012 compared to $2.13 billion for the fourth quarter of 2011. For 2012, product sales increased 16 percent to $9.40 billion compared to $8.10 billion in 2011. The increase in product sales was due primarily to Gilead's antiviral franchise, resulting from increased sales of Complera®/Eviplera® (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir disoproxil fumarate 300 mg), Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) and Truvada® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) as well as the launch of Stribild® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg).

    investorsDOTgileadDOTcom/preview/phoenixDOTzhtml?c=69964&p=irol-newsArticle&ID=1781144&highlight=

    Slides 56
    gileadDOTcom/pdf/4Q12EarningsSlides.pdf

 
GILD
81.37-0.15(-0.18%)Sep 23 4:00 PMEDT